| abstract |
Compounds of formula I (see formula I) or their stereoisomer, tautomer or salt acceptable for pharmaceutical use are described, where j, k, U, W, R, R1, R2, R3, R4, R6, R7 and R7a are as described above in the specification; In addition, the method for inhibiting aspartyl protease is described, and in particular, the methods for treating cardiovascular diseases, cognitive and neurodegenerative diseases; methods for treating cognitive and neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or an m1 agonist or muscarinic m2 antagonist are also described. |